Solanezumab is a monoclonal antibody being studied as a potential therapy for Alzheimer’s disease.
The secondary analysis of the trials data demonstrated slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer’s disease but not in patients with moderate Alzheimer’s disease.
Lilly chairman, president and chief executive officer John Lechleiter said solanezumab studies did not meet primary endpoints but the company is encouraged by the pooled data that show a slowing of cognitive decline.
"We intend to discuss these data with regulatory authorities to gain their insights on potential next steps," Lechleiter added.
Lilly science and technology executive vice president and research laboratories president Jan Lundberg said Lilly is committed to finding medicines that alter the underlying pathology of Alzheimer’s disease.
"We believe the pooled data support the amyloid hypothesis, as these are the first Phase 3 data with an anti-beta amyloid agent that appear to show a slowing of cognitive decline," Lundberg added.
EXPEDITION studies data are being analyzed by the Alzheimer’s Disease Cooperative Study (ADCS), an academic national research consortium that facilitates the discovery, development and testing of new drugs to treat Alzheimer.